An Interventional, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy and Safety of Infliximab in Subject With Moderate-to-Severe Refractory Intestinal Behcet's Disease
Phase of Trial: Phase III
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Infliximab (Primary)
- Indications Behcet's syndrome
- Focus Registrational; Therapeutic Use
- Acronyms BEGIN
- Sponsors Janssen Biotech
- 31 Oct 2017 Planned number of patients changed from 37 to 31.
- 31 Oct 2017 Planned End Date changed from 31 Jan 2019 to 9 Aug 2018.
- 05 Sep 2017 Planned number of patients changed from 41 to 37.